The loss of hair during cancer treatments is a traumatic and psychologically devastating side effect and a constant reminder of the disease.
Paxman's cooling caps aim to minimise patient distress with figures showing that on average 70-90% of patients who use the system do not require a wig.
Paxman Coolers will be unveiling their new NPAX1 scalp cooler at Arab Health - attracting potential business partners from across the Middle East.
Made from lightweight, silicone tubing, the Paxman scalp cooling cap is soft and flexible creating a snug yet comfortable cap during treatment.
Moulding to all head shapes and sizes, the specially developed liquid coolant passes through the cap extracting heat from the patient's scalp, ensuring the scalp remains at an even, constant temperature; minimising hair loss.
The caps are worn 30 minutes before the start of chemotherapy, during the treatment itself and for a period of time after infusion of the chemotherapy depending on the toxicity of the drugs.
With straightforward programming and controls, including recommended cooling time guides, the new generation cooling cap system is not only effective, but uncomplicated.
The cap is connected to a cutting edge and easy to use refrigeration system which uses an up-to-the-minute touch screen display, and simple switch operation, making it easy for both the patient and staff to operate.
Managing Director Glenn Paxman is hoping Arab Health will allow the company to expand their links with the Middle East:
"Arab Health will allow us to platform our products on an international stage and establish links with potential business partners from across the UAE; enabling us to expand on our already buoyant overseas market."
Leaflets will also be available for the new NPAX2 - the dual cooling cap patient system from Paxman, which allows two patients to be treated simultaneously from one system.
To meet with Paxman Coolers at Arab Health or for further information on their products, please visit their website www.paxman-coolers.com or contact them at info@paxman-coolers.com
Arab Health is the largest healthcare event in the Middle East and will be taking place between 25-28 January 2010 at the Dubai International Convention Centre. Throughout the show Paxman will be located on the UK Pavilion, hall xx stand xx.
Browse
related articles
The future in hair loss prevention travels to the Middle East
- United Arab Emirates: Monday, December 07 - 2009 at 16:06
- PRESS RELEASE
Related content
The next generation in scalp coolers will be showcased by Paxman Coolers next month, providing cancer patients with the best possible chance of retaining their hair whilst undergoing chemotherapy treatment.
Article Options
Log in to request more information from Paxman Coolers
Posted by Husam OdiabatMonday, December 07 - 2009 at 16:06 UAE local time (GMT+4)
Replication or redistribution in whole or in part is expressly prohibited without the prior written consent of AME Info FZ LLC / Emap Limited.
This article was updated on Mon Jan 17 2011.
Notes and Media Contacts »
More information about Paxman Coolers:
Cancer chemotherapy affects rapidly dividing cells and at any given time, 90% of human hair follicles are in the actively dividing phase. Hair loss frequently occurs due to partial or total atrophy of the hair root bulb, causing constriction of the hair shaft, which then breaks off easily.
Cooling the scalp during selected chemotherapy regimes has been shown to reduce or prevent otherwise inevitable total hair loss.
Other systems based on this principle utilise packs of crushed ice and frozen gel caps. These have the disadvantage of being uncomfortable, heavy to wear and are applied to the scalp at an unbearable temperature of -25°C which heats rapidly when in contact with the scalp, and perhaps more important however is the application and monitoring aspect, which is very time consuming for nursing staff.
Thermocircular systems utilised a cold cap of circulating glycol in the past as long ago as 1982. Paxman Coolers have applied the same principles using modern technology to produce the Paxman Scalp Cooler. A system that works, is user friendly, is a cost effective way to reduce the need to supply wigs, and has been accepted by doctors, nursing staff and patients alike. Previous problems associated with cold therapy treatments have been eliminated.
For more information contact:
Victoria Haley
Medilink Yorkshire and Humber:
Tel: 00 44 114 2329279
Cancer chemotherapy affects rapidly dividing cells and at any given time, 90% of human hair follicles are in the actively dividing phase. Hair loss frequently occurs due to partial or total atrophy of the hair root bulb, causing constriction of the hair shaft, which then breaks off easily.
Cooling the scalp during selected chemotherapy regimes has been shown to reduce or prevent otherwise inevitable total hair loss.
Other systems based on this principle utilise packs of crushed ice and frozen gel caps. These have the disadvantage of being uncomfortable, heavy to wear and are applied to the scalp at an unbearable temperature of -25°C which heats rapidly when in contact with the scalp, and perhaps more important however is the application and monitoring aspect, which is very time consuming for nursing staff.
Thermocircular systems utilised a cold cap of circulating glycol in the past as long ago as 1982. Paxman Coolers have applied the same principles using modern technology to produce the Paxman Scalp Cooler. A system that works, is user friendly, is a cost effective way to reduce the need to supply wigs, and has been accepted by doctors, nursing staff and patients alike. Previous problems associated with cold therapy treatments have been eliminated.
For more information contact:
Victoria Haley
Medilink Yorkshire and Humber:
Tel: 00 44 114 2329279
Disclaimer »
Articles in this section are primarily provided directly by the companies appearing or PR agencies which are solely responsible for the content. The companies concerned may use the above content on their respective web sites provided they link back to http://www.ameinfo.com
Any opinions, advice, statements, offers or other information expressed in this section of the AMEinfo.com Web site are those of the authors and do not necessarily reflect the views of AME Info FZ LLC / Emap Limited. AME Info FZ LLC / Emap Limited is not responsible or liable for the content, accuracy or reliability of any material, advice, opinion or statement in this section of the AMEinfo.com Web site.
For details about submitting your stories, please read the guide - all content published is subject to our terms and conditions
